TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

Size: px
Start display at page:

Download "TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012"

Transcription

1 TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following disclosures to make: No conflict of interests No relevant financial relationships with any commercial companies pertaining to this educational activity 1

2 Challenges of TB Treatment in Special Populations in Corrections TB in Prisons and Jails: Get Out TB Free Albuquerque, New Mexico Marcos Burgos MD Medical Director TB Program New Mexico, Department of Health November 28,

3 Learning Objectives Epidemiology of TB Identify barriers to TB control in prisons Risk factors for TB in Prisons Special medical situations in prisons Illustrative cases of TB and other co morbidities 5 Rationale for Strengthening TB Control and Prevention in Prisons Inmates who have TB disease or LTBI can be treated before they are released into the community The correctional setting can be a primary source of health information, intervention, and management of chronic diseases 3

4 30,000 Reported TB Cases United States, * 25,000 No. of Cases 20,000 15,000 10,000 5,000 0 Year *Updated as of July 21, 2011 Countries of Birth of Foreign born Persons Reported with TB, United States, 2010 Other Countries 38% Mexico (23%) Philippines (11%) Haiti (3%) Guatemala (3%) China (5%) Vietnam (8%) India (9%) 4

5 Challenges to TB control in the prisons Logistical and management structures Personal perception, bias, stigma Recognition of basic human rights Revolving door Lack of expertise 9 High Percentage of TB Cases in Incarcerated Persons in the US In 2008, 2.4 million people were incarcerated in United States jails or prisons 25 % of inmates are foreign born 3.2% of all TB cases nationwide occurred among residents of correctional facilities in 2003 BMC Public Health. 2010; 10:

6 Tuberculosis and incarceration TB in corrections is 4 to 5 times greater than outside corrections Inmates at high risk of TB Foreign born, substance abuse, lower socio economical status, other medical conditions Congregate setting Overcrowding poor ventilation Frequent inmate movement 11 Relative Risk for developing TB by various risk factors 6

7 Prison populations Demographics: Convergence of risk groups Male Young age groups High unemployment rate/low income persons Low education level High rates drug abuse and alcoholism High rates of HIV & STDs High rates of mental illness and homelessness Frequent close contacts and recent exposure to active cases Bureau of Justice Statistics, Special Report, Correctional Population Large numbers incarcerated people now and in the future Chronic illness Mental illness Addiction Incarceration of undocumented immigrants 14 7

8 Medical problems reported by prison inmates by gender and age, 2004 Medical problem All inmates Male Female Arthritis Asthma Cancer Diabetes Heart problems Hypertension Kidney problems Liver problems Paralysis Stroke Hepatitis HIV STDs Tuberculosis U.S. Department of Justice, Bureau of Justice statistics, TB & Special Medical Conditions in Corrections 8

9 36 year old male in Jail for 2 months, history of drug use, ETOH abuse, complaining of weight loss, 30 pounds in 6 months, some productive cough, fever and chills Treated for pneumonia twice Diagnostic studies: AFB smear 3+; LFT elevated X 3 nl TB & Special Medical Conditions in Corrections HIV positive, CD4 46, viral load 800,000 9

10 HIV in Prisons, The rate of HIV/AIDS among state and federal prison inmates declined from 194 cases per 10,000 inmates in 2001 to 146 per 10,000 at yearend AIDS-related deaths among all state and federal prison inmates declined from 24 deaths per 100,000 inmates in 2001 to 5 per 100,000 in AIDS-related deaths in state prisons declined from 89 in 2009 to 69 in 2010 among males, from 70 to 43 among black non- Hispanics, and from 87 to 60 among all state inmates age 35 or older. California, Florida, New York, and Texas each reported holding more than 1,000 inmates with HIV/AIDS at yearend These states held 51% (9,492) of all state prisoners with HIV/AIDS. U.S. Department of Justice, Office of Justice Programs. Bureau of Justice Statistics,

11 Current CDC / IDSA / ATS guidelines duration of therapy for HIV related TB Standard 6 month regimens for most patients Extend therapy to 9 months for patients with + cultures at 2 months and cavitation or delayed clinical response Recommendations: frequency of treatment Always use directly observed therapy for patients with HIV related TB Target patients with advanced HIV disease for more frequent therapy Daily for the first 2 months Thrice weekly or daily during the continuation phase MMWR 2002;51:

12 36 year old male with pulmonary tuberculosis, LFT elevated X 3 nl, Started on RIPE, tolerated treatment well When do we start HIV treatment? CD4 cell count at TB diagnosis and mortality rate 120 Mortality rate (per 100 person-years) > 350 CD4 cell count Lancet 1999;353:

13 CDC Recommendations for use of antiretroviral therapy during TB treatment CD4 cell count at TB diagnosis < 200 < > 350 ART during TB treatment Start ASAP Monitor, consider starting ART Monitor CD4 & clinical status Management issues: antiretroviral therapy during TB therapy Challenge of adherence to multidrug therapy for both diseases Overlapping drug toxicity profiles Drug interactions Immune reconstitution (paradoxical) reactions Need for coordination between TB and HIV treatment programs 13

14 36 year old male with pulmonary tuberculosis, Hep C +, LFT elevated X 3 nl, Started on RIPE, tolerated treatment well What ART should we start? Adherence in treatment of TB and HIV DOT program for TB builds strong relationships with patients frequent contact, attention to other aspects of care (housing, etc.) Once-daily ART now possible Provide directly observed ART at the same time as TB medications in prison Educate health providers in prison about ART, side effects 14

15 Overlapping side effect profiles of first line TB drugs and ART drugs Possible causes Side effect TB drugs ART drugs Skin rash Nausea, vomiting Hepatitis Leukopenia, anemia PZA, RIF, INH PZA, RIF, RBT, INH PZA, RIF, RBT, INH RBT, RIF NVP, EFV, ABC AZT, PIs NVP, PIs, IRIS AZT 46 year old male from Mexico, admitted because intractable diarrhea, weight loss of 60 pound in 6 months, some productive cough, fever and chills Diagnostic studies: AFB smear +; HIV + CD4 18; VL > 800,000 Efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir 300mg 15

16 Summary: HIV, TB drug interaction Drug interactions in HIV-TB should not prevent HIV-TB treatment Drug interactions should be managed, not avoided Close collaboration with correctional physicians and nurses TB & Special Medical Conditions in Corrections 16

17 TB Case 44 year old male with history of alcohol abuse and homelessness for 15 years, in prison for about 9 months Productive cough for 3 months and blood tinged sputum The patient has a history of large reaction to a skin test in prison in Arizona The patient has lost 40 pounds in the last year CXR CXR 17

18 TB case TB case PMH Diabetes (HbA1C 10), Hypertension Chronic depression, Bipolar disorder PSH History of IVDU History of alcoholism for 20 years with most of those years homeless Smoker 1 1/2 packs daily for 30 years 18

19 TB case The patient is started in 4 drugs AST 64, ALT 61 2 weeks later: AST 286, ALT 287, platelets 160, direct bilirubin 2.5 Treatment stopped, AFB smears 3+ 2 weeks later, AST 568, ALT 638, Platelets 120 TB case HVC + HVC viral load > 3,000,000 2 weeks latter AST 206, ALT 261 Patient started on Amikacin, ETB, Moxifloxacin. 9/16/09 patient develops a generalized maculo papular rash, TB drugs stopped AST 285, ALT

20 TB Case rash resolved, patient developed rash when amikacin is introduced AST 315, ALT 346, Platelets 132 TB case 1 week latter AST 228, ALT 261, rash resolved The patient started on, rifabutin, ETB and levofloxacin sequentially Two weeks latter AST 252, ALT 255, Platelets 91 and patient seems to be tolerating treatment well 20

21 Hepatic C The hepatitis C virus is the leading cause of liver cancer and the most common bloodborne infection in the US, affecting approximately 3.2 million people. About 25% of persons living with HIV and about 30% of those living with Hepatitis C spent time in correctional facilities. Among prisoners, 12% and 30% are infected with the virus in the U.S. HVC and TB treatment Few studies have evaluated the impact of HCV infection during treatment for TB In Florida among 128 patients, 30% of hepatitis C infected individuals developed hepatotoxicity compared with 11% among uninfected individuals Hepatitis C was an independent risk factor for the development of hepatotoxicity, elevating the risk fivefold The risk of hepatotoxicity more than 14 fold in HVC/HIV coinfection An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy,

22 Evaluation and treatment of Hep C Antiviral therapy is generally indicated for inmates with chronic hepatitis C if they have no contraindications to treatment and present with at least one of the following: Genotype 1 and liver biopsy result with evidence of progressive fibrosis Genotype 2 or 3 (with no biopsy performed) Genotypes 4, 5, or 6: The best approach to management of these cases is not clearly defined by the medical literature. HCV should be the same as for genotype 1 as noted above. Various co infections or co morbidities, such as cirrhosis and renal disease, may affect treatment decisions Expert advice and guidance should be obtained Federal Bureau of Prisons Clinical Practice Guidelines, Clinical Guidelines, March Mode of transmission of Hep C Percutaneous Exposure to Infectious Blood (primary mode) Injection drug use Transmission of contaminated blood products (prior to July 1992) Tattooing with shared sharps in jails or prisons (potential mode) Other Modes of Transmission (inefficient) Sexual contact (increased risk for inmates with history of STD or multiple sexual partners) Congenital transmission (risk of 5 6%) Ways HCV is not transmitted Breast feeding Kissing, sneezing, hugging, coughing Food or water Casual contact, including sharing eating utensils or drinking glasses 22

23 TB & Special Medical Conditions in Corrections HIV HVC DM Renal insufficiency Diabetes and TB 80,000 of prisoners have diabetes, a prevalence of 4.8% Diabetes accelerates latent TB active TB (3x) Diabetes makes TB harder to diagnose and treat Diabetes leads to poor TB outcomes Diabetes Management in Correctional Institutions, American Diabetes Association, 2012, care.diabetesjournals.org 23

24 TB and Diabetes Harder to Find More likely to have exclusively lower lobe disease Harder to Treat More likely to have cavitary disease More likely to remain smear positive at 8 weeks of treatment Relapse Rates? Death during TB treatment? Dooley KE, Am J Trop Med Hyg Apr;80(4):634 9, Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis TB infection and renal insufficiency TB infection among US chronic dialysis patients, is not infrequent Patients with renal insufficiency should be screen for LTBI Ethic minority groups have a higher prevalence of renal insufficiency and risk of infection with tuberculosis Patients with renal insufficiency are at increase risk of developing tuberculosis 24

25 Treatment of Active TB in patients with reduced renal function In general INH, RIF can be used at normal doses in renal impairment Pyridoxine should be give to prevent peripheral neuropathy PZA and ETB 3X weekly Give treatment after hemodyalsis to avoid premature drug removal TB & Special Medical Conditions in Corrections HIV HVC DM Renal insufficiency 25

Case Management of the TB/HIV Infected Patient

Case Management of the TB/HIV Infected Patient TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected

More information

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer The Public Health Impact of TB in the Correctional System Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer The Public Health Impact of TB in the Correctional System

More information

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of

More information

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures

More information

Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009

Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD

More information

has the following disclosures to make:

has the following disclosures to make: CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Contact Investigation in the Correctional Setting Jessica Quintero, BAAS March 24, 2011 Jessica Quintero, BAAS has the following disclosures to make: No

More information

TB trends and TB genotyping

TB trends and TB genotyping Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures

More information

Tuberculosis Populations at Risk

Tuberculosis Populations at Risk Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017 Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Treatment of Latent TB Infection (LTBI)

Treatment of Latent TB Infection (LTBI) Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious

More information

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 5/6/2011 Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Epidemiology of Substance Abuse and Tuberculosis: Where is the Problem? Debra Stephens, RN, BSN, MPH April 27, 2011 Debra Stephens,

More information

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012 Disclosures TB and CoMorbidities Challenges and Opportunities E. Jane Carter, M.D. Associate Professor of Medicine Alpert School of Medicine, Brown University Providence, Rhode Island No financial disclosures

More information

Anti Tuberculosis Medications: Side Effects & adverse Events

Anti Tuberculosis Medications: Side Effects & adverse Events Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,

More information

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38 2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

Arizona Annual Tuberculosis Surveillance Report

Arizona Annual Tuberculosis Surveillance Report Arizona Annual Tuberculosis Surveillance Report 2014 Table of Contents I. Executive Summary 1 II. Case Rates 3 III. Cases and Case Rates by Race and Ethnicity 4 IV. Cases by Gender 4 V. Cases and Case

More information

Tuberculosis Epidemiology

Tuberculosis Epidemiology Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline

More information

Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18

Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18 Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department

More information

When Can Isolation Be Discontinued?

When Can Isolation Be Discontinued? When Can Isolation Be Discontinued? - It Depends on the Patient and the Setting. Masae Kawamura M.D. and Barbara Seaworth M.D. Texas: (800) TEX-LUNG New Jersey: 973-972-3270? HNTC Consultation Line California:

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

TB in Foreign Born and High Risk Populations

TB in Foreign Born and High Risk Populations TB Nurse Case Management San Antonio, Texas December 8-10, 2009 TB in Foreign Born and High Risk Populations John J. Nava, M.D. December 9, 2009 Tuberculosis in High Risk Populations and the Foreign Born

More information

Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination

Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Haley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic

Haley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic Haley Blake Sage Nagai, MPH Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic Discuss the prevalence of tuberculosis in Clark County Describe factors influencing

More information

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard

More information

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015 Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian

More information

My heart is racing. Managing Complex Cases. Case 1. Case 1

My heart is racing. Managing Complex Cases. Case 1. Case 1 Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from

More information

TB Nurse Case Management San Antonio, Texas April 9-11, 2013

TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,

More information

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant

More information

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015 Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Epidemiology Robert Petrossian July 18, 2012 Robert Petrossian has the following disclosures to make: No conflict of interests No relevant

More information

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures

More information

TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011

TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Co-morbidities in Substance Abuse that Impact Managing TB Lisa Armitige, MD, PhD April 27, 2011 Lisa Armitige, MD, PhD has the following

More information

Rehuka Khurana, MD, MPH has the following disclosures to make:

Rehuka Khurana, MD, MPH has the following disclosures to make: Case Presentation Steps to a Systematic Approach to Diagnosis of TB Case Presentation Steps to a Systematic Approach to Diagnosis of TB Renuka Khurana, MD, MPH March 13, 2015 TB for Pulmonologist March

More information

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:

More information

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients

More information

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests

More information

MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015

MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD

Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV

More information

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make: TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection

Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Krista Powell, MD, MPH Co-Project Officer, National Surveillance for Severe Adverse Events Associated with LTBI Treatment Lead,

More information

Who is at Risk of TB?

Who is at Risk of TB? Who is at Risk of TB? Lisa Armitige, MD, PhD September 20, 2017 Screening for Tuberculosis Infection September 20, 2017 Harlingen, TX EXCELLENCE EXPERTISE INNOVATION Lisa Armitige, MD, PhD has the following

More information

Pediatric TB Intensive Houston, Texas October 14, 2013

Pediatric TB Intensive Houston, Texas October 14, 2013 Pediatric TB Intensive Houston, Texas October 14, 2013 Diagnosis and Management of Tuberculosis in Adolescents Andrea T. Cruz, MD, MPH Sections of Infectious Diseases & Emergency Medicine October 14, 2013

More information

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Chapter 1 Overview of Tuberculosis Epidemiology in the United States Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States... 3 TB Disease Trends in the United

More information

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now! EXCELLENCE EXPERTISE INNOVATION Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now! Barbara J Seaworth, MD, Medical Director, Heartland National TB Center Professor,

More information

Contact Investigation

Contact Investigation Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period

More information

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION

More information

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005 1 Investigation of Contacts of Persons with Infectious Tuberculosis, 2005 Daniel P. Dohony, MPH Division of Tuberculosis Elimination Centers for Disease Control and Prevention and Philadelphia TB Control

More information

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

U.S. Preventive Services Task Force Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults

U.S. Preventive Services Task Force Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Preventive Services Task Force Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults Centers

More information

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

TB-Free California: How close are we? How can we get closer?

TB-Free California: How close are we? How can we get closer? TB-Free California: How close are we? How can we get closer? California TB Controllers Association April 21, 2015 Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology Section Acknowledgments Local

More information

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis? Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able

More information

Managing the Patients Response to TB Treatment

Managing the Patients Response to TB Treatment Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has

More information

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner

More information

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016 Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

2016 Annual Tuberculosis Report For Fresno County

2016 Annual Tuberculosis Report For Fresno County 206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 TB and Diabetes Barbara Seaworth, MD November 13, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant

More information

SA TB Guidelines The interface with Advanced Clinical Care

SA TB Guidelines The interface with Advanced Clinical Care SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop

More information

CLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives

CLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb http://www.umdnj.edu/globaltb/coretbresources.htm Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J.

More information

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014 Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB

More information

8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:

8/28/2017. Learning Objectives. After attending this presentation, learners will be able to: New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to

More information

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division

More information

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254) Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

What is Hepatitis C Virus (HCV)?

What is Hepatitis C Virus (HCV)? HEPATITIS C VIRUS (HCV) What is Hepatitis C Virus (HCV)? Hepatitis is an inflammation (swelling or tenderness) of the liver. Hepatitis C virus (HCV) is the most common form of viral hepatitis and usually

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis

More information

At the end of this session, participants will be able to:

At the end of this session, participants will be able to: Advanced Concepts in Pediatric Tuberculosis: Infection Control, Source Case and Contact Investigation Ana M. Alvarez, M.D. Associate Professor Division of Pediatric Infectious Diseases and Immunology University

More information

The Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University

The Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University The Elimination of Tuberculosis Richard E. Chaisson, MD Center for TB Research Center for AIDS Research Johns Hopkins University Disclosures Spouse owns Merck stock Consultant: Merck Research funding:

More information

Treatment of Tuberculosis, 2017

Treatment of Tuberculosis, 2017 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

LTBI in Special Populations John Nava, MD October 5, 2010

LTBI in Special Populations John Nava, MD October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John

More information